BACKGROUND:Efavirenz (EFV) is an antiretroviral (ARV) drug associated with neuropsychological effects. Limited data describing the long-term impact of EFV-based regimens on neuropsychological performance over more than 3 years are available. METHODS: We enrolled a subset of participants from a large initially EFV placebo-controlled trial of therapies for HIV subjects naïve to ARV treatment (A5095). Clinical follow-up continued for 184 weeks of study. Subjects were assessed with brief neuropsychological testing, a symptom questionnaire of EFV-associated symptoms, the Pittsburgh Sleep Index, Center for Epidemiologic Studies-Depression Scale, and an anxiety rating interview. RESULTS: Over 184 weeks on EFV, the median NPZ3 score in 86 evaluable patients improved from baseline by +0.5 (p < .01); all components improved, although higher EFV levels were associated with slightly lower responses. Overall symptom scores did not change, while EFV-associated CNS symptoms increased (p = .01). Median change of bad dream sleep scores and anxiety increased from the baseline while global depression score decreased. CONCLUSIONS: In participants who continued EFV-based regimens, neuropsychological performance improvement from baseline was maintained over 3 years. EFV-based treatment was generally well tolerated, but small increases from baseline in EFV-associated symptoms, bad dreams, and anxiety were detected.
RCT Entities:
BACKGROUND:Efavirenz (EFV) is an antiretroviral (ARV) drug associated with neuropsychological effects. Limited data describing the long-term impact of EFV-based regimens on neuropsychological performance over more than 3 years are available. METHODS: We enrolled a subset of participants from a large initially EFV placebo-controlled trial of therapies for HIV subjects naïve to ARV treatment (A5095). Clinical follow-up continued for 184 weeks of study. Subjects were assessed with brief neuropsychological testing, a symptom questionnaire of EFV-associated symptoms, the Pittsburgh Sleep Index, Center for Epidemiologic Studies-Depression Scale, and an anxiety rating interview. RESULTS: Over 184 weeks on EFV, the median NPZ3 score in 86 evaluable patients improved from baseline by +0.5 (p < .01); all components improved, although higher EFV levels were associated with slightly lower responses. Overall symptom scores did not change, while EFV-associated CNS symptoms increased (p = .01). Median change of bad dream sleep scores and anxiety increased from the baseline while global depression score decreased. CONCLUSIONS: In participants who continued EFV-based regimens, neuropsychological performance improvement from baseline was maintained over 3 years. EFV-based treatment was generally well tolerated, but small increases from baseline in EFV-associated symptoms, bad dreams, and anxiety were detected.
Authors: Heather J Ribaudo; David W Haas; Camlin Tierney; Richard B Kim; Grant R Wilkinson; Roy M Gulick; David B Clifford; Catia Marzolini; Courtney V Fletcher; Karen T Tashima; Daniel R Kuritzkes; Edward P Acosta Journal: Clin Infect Dis Date: 2005-12-27 Impact factor: 9.079
Authors: David B Clifford; Scott Evans; Yijun Yang; Edward P Acosta; Karl Goodkin; Karen Tashima; David Simpson; David Dorfman; Heather Ribaudo; Roy M Gulick Journal: Ann Intern Med Date: 2005-11-15 Impact factor: 25.391
Authors: K T Tashima; A M Caliendo; M Ahmad; J M Gormley; W D Fiske; J M Brennan; T P Flanigan Journal: J Infect Dis Date: 1999-09 Impact factor: 5.226
Authors: Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Christina Lalama; Bruce R Schackman; William A Meyer; Edward P Acosta; Jeffrey Schouten; Kathleen E Squires; Christopher D Pilcher; Robert L Murphy; Susan L Koletar; Margrit Carlson; Richard C Reichman; Barbara Bastow; Karin L Klingman; Daniel R Kuritzkes Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: S Staszewski; J Morales-Ramirez; K T Tashima; A Rachlis; D Skiest; J Stanford; R Stryker; P Johnson; D F Labriola; D Farina; D J Manion; N M Ruiz Journal: N Engl J Med Date: 1999-12-16 Impact factor: 91.245
Authors: Ned Sacktor; Michael P McDermott; Karen Marder; Giovanni Schifitto; Ola A Selnes; Justin C McArthur; Yaakov Stern; Steve Albert; Donna Palumbo; Karl Kieburtz; Joy A De Marcaida; Bruce Cohen; Leon Epstein Journal: J Neurovirol Date: 2002-04 Impact factor: 2.643
Authors: Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Yijia Li; Zheng Wang; Yu Cheng; James T Becker; Eileen Martin; Andrew Levine; Leah H Rubin; Ned Sacktor; Ann Ragin; Ken Ho Journal: AIDS Date: 2019-07-01 Impact factor: 4.177
Authors: Katie R Mollan; Marlene Smurzynski; Joseph J Eron; Eric S Daar; Thomas B Campbell; Paul E Sax; Roy M Gulick; Lumine Na; Lauren O'Keefe; Kevin R Robertson; Camlin Tierney Journal: Ann Intern Med Date: 2014-07-01 Impact factor: 25.391
Authors: Ellen M McDonagh; Johnathan L Lau; Maria L Alvarellos; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2015-07 Impact factor: 2.089
Authors: Uriel Sandkovsky; Anthony T Podany; Courtney V Fletcher; Andrew Owen; Angela Felton-Coleman; Lee C Winchester; Kevin Robertson; Susan Swindells Journal: J Antimicrob Chemother Date: 2016-09-21 Impact factor: 5.790
Authors: Qing Ma; Florin Vaida; Jenna Wong; Chelsea A Sanders; Yu-ting Kao; David Croteau; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina M Marra; Justin C McArthur; Susan Morgello; David M Simpson; Robert K Heaton; Igor Grant; Scott L Letendre Journal: J Neurovirol Date: 2015-09-25 Impact factor: 2.643